Press releases
- Rigel Pharmaceuticals Provides Business Update
- Rigel to Present at the 39th Annual J.P. Morgan Healthcare Conference
- Rigel Announces Two Posters Highlighting TAVALISSE at the 62nd ASH Annual Meeting & Exposition
- Rigel and Medison Announce Health Canada Approval of TAVALISSE®, an Oral Medication for the Treatment of Adults with Chronic Immune Thrombocytopenia
- Rigel Finalizes the Study Design of its Ongoing Phase 3 Clinical Trial of Fostamatinib in Warm Autoimmune Hemolytic Anemia
- Rigel to Present at the Jefferies Virtual London Healthcare Conference
- Rigel Reports Third Quarter 2020 Financial Results and Provides Business Update
- Rigel Announces Conference Call and Webcast to Report Third Quarter 2020 Financial Results and Business Update
More ▼
Key statistics
On Friday, Rigel Pharmaceuticals Inc (RIGLD:DEU) closed at 3.10, -23.27% below its 52-week high of 4.04, set on Jul 14, 2020.
52-week range
Markit short selling activity
Open | 3.08 |
---|---|
High | 3.20 |
Low | 3.06 |
Bid | 3.16 |
Offer | 3.16 |
Previous close | 3.08 |
Average volume | 3.16k |
---|---|
Shares outstanding | 168.93m |
Free float | 168.39m |
P/E (TTM) | -- |
Market cap | 604.77m USD |
EPS (TTM) | -0.1648 USD |
Data delayed at least 15 minutes, as of Jan 15 2021 20:52 GMT.
More ▼